NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Expanding At A CAGR Of 30.1% For Forecast Period From 2017 To 2025 : Grand View Research Inc.

NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Expanding At A CAGR Of 30.1% For Forecast Period From 2017 To 2025 : Grand View Research Inc.

“Grand View Research, Inc. – Market Research And Consulting”
According to report published by Grand View Research, Increasing demand for noninvasive diagnostic tools coupled with rising levels of patient awareness is expected to augment development of NASH (Non-alcoholic Steatohepatitis) biomarkers over the forecast period.

According to a report,” NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis By Type (Serum, Hepatic Fibrosis, Apoptosis, Oxidative Stress), By End-Use (Pharma & CRO Industry, Hospitals, Diagnostic Labs), And Segment Forecasts, 2018 – 2025 ” published by Grand View Research, Inc., The global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to reach USD 2.09 billion by 2025, according to a new report by Grand View Research, Inc. Increasing incidence of chronic liver diseases is expected to propel the demand for NASH biomarkers over the forecast period. The National Health and Nutrition Examination Survey recently found that approximately 30% of Nonalcoholic Fatty Liver Diseases (NAFLD) occurred in the U.S. alone. This disease remains undiagnosed, as a liver can remain fatty without any change in its function. However, it can progress into a serious condition, known as nonalcoholic steatosis that may result in liver failure. NASH is characterized by inflammation and irreversible cell death.

Key Takeaways from the report:

Serum biomarkers held majority of the revenue share as of 2016 owing to its high efficacy in NASH diagnosis

Gamma-glutamyl transferase is the serum biomarker that is usually higher in patients with fatty liver diseases, resulting in liver failure.

Increasing list of patients awaiting liver transplantation is a major contributing factor for the growing demand of noninvasive biomarker tests over the forecast period

Pharmaceutical and contract research industry dominate the end-use segment owing to ample availability of R&D funding and ongoing research projects for the development NASH drugs

Industry participants are focusing on development of cost-effective solutions, thereby increasing R&D activities for development of novel technologies

U.S. NASH biomarkers market revenue by type, 2014 – 2025 (USD million)

U.S. NASH biomarkers market revenue by type, 2014 - 2025 (USD million)

Browse More Reports in Clinical Diagnostics Industry: 

Heart Attack Diagnostics MarketIncreasing geriatric population, sedentary lifestyle and high prevalence of coronary artery diseases represent the factors escalating the Heart Attack Diagnostics market growth.

HIV Diagnostics Market Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. 

Global NASH biomarkers market revenue, by region, 2016 (%)

Global NASH biomarkers market revenue, by region, 2016 (%)

 

Rising demand for non-invasive diagnostic tools for detection of NASH is another driver of market. Traditionally, liver biopsy is performed to diagnose NAFLD and its degenerative condition, that is, NASH. This technique is expensive and invasive in nature. This disadvantage has led to the development of noninvasive and cost-efficient diagnostic techniques such as biomarker tests. It is observed that many key companies spent significantly on research and development activities to introduce novel biomarker tests. These factors are expected to propel NASH biomarkers market in the coming years.

The drug manufacturers are focusing on tapping unmet medical needs for treatment of NASH to capture additional market share. Strategic collaborations, expansion in developing geographies, and technological advancements are some of the key strategies adopted by existing market players.

Grand View Research has segmented NASH biomarkers market on the basis of the type, end-use, and region:

NASH Biomarkers Type Outlook (Revenue, USD Million, 2014 – 2025)

  • Serum biomarkers

  • Hepatic fibrosis biomarkers

  • Apoptosis biomarkers

  • Oxidative stress biomarkers

  • Other biomarkers

NASH Biomarkers End-use Outlook (Revenue, USD Million, 2014 – 2025)

  • Pharma & CRO industry

  • Hospitals

  • Diagnostic labs

  • Academic research institutes

NASH Biomarkers Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Mexico

    • Brazil

  • MEA

    • South Africa

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

For more information: www.grandviewresearch.com

 

 

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/non-alcoholic-steatohepatitis-nash-biomarkers-market